用ＲＴＰＣＲ从ＣＶＢ３ 感染细胞中扩增出ＶＰ１ 片段，重组入真核表达质粒ｐｃＤＮＡ３ 中，转化大肠杆菌Ｃ６００，扩增后的质粒经ＣｓＣｌ 密度梯度离心纯化，体外转染ＣＯＳ７ 细胞，用ＳＤＳＰＡＧＥ和Ｗｅｓｔｅｒｎｂｌｏｔｔｉｎｇ 检测表达产物；并经胫骨前肌注射小鼠，每鼠１００μｇ／ 次，隔４ 周加强一次，共３ 次。免疫后不同时间检测抗体、淋巴细胞增殖反应等免疫指标。结果显示重组质粒体外转染真核细胞表达ＶＰ１ 蛋白，免疫小鼠后产生了特异性抗体和淋巴细胞增殖反应。表明ＣＶＢ３ ＶＰ１ ＤＮＡ疫苗获得初步有效结果。 VP1 fragment was amplified from infected cells of CVB3 by RTPCR and recombined into eukaryotic expression plasmid pcDNA3. The recombinant plasmid was transformed into E. coli C600. The amplified plasmid was purified by CsCl density gradient centrifugation and transfected into COS7 cells in vitro. SDS  PAGE and Westernblotting detection of expression products; and mice by anterior tibialis injection, each mouse 100μg / time, once every 4 weeks, a total of 3 times. Antibodies at different times after immunization, immune response such as lymphocyte proliferation response. The results showed that recombinant plasmid transfected eukaryotic cells in vitro expression of VP1 protein, immune mice produced specific antibodies and lymphocyte proliferation response. This indicated that the CVB3 VP1 DNA vaccine obtained preliminary and effective results.